Trial Profile
A Phase 2, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-line Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2021
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors Kadmon Corporation
- 12 Apr 2017 Results published in a Kadmon Holdings media release.
- 12 Apr 2017 Results published in the Cutting Edge section of the Journal of Immunology, according to a Kadmon Holdings media release.
- 16 Nov 2016 Results assessing Psoriasis Area and Severity Index (PASI) scores and levels of cytokines in plasma sample, presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals